Soldano Ferrone

Recent Publications

• Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C.   Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.Clin Cancer Res, 16:800-813, 2010.  PMCID: PMC2842003.
• Goto Y, Arigami T, Murali R, Scolyer RA, Tanemura A, Takata M, Turner RR, Nguyen L, Nguyen, T, Morton DL, Ferrone S, Hoon DS.  High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma.  Pigment Cell Melanoma Res, 23:137-140, 2010.  PMCID: PMC2879036.
• Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL.  A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.Clin Cancer Res, 16:825-834, 2010.  PMCID: PMC2818599.
• Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, Kloor M.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.Int J Cancer, 127:889-898, 2010.  PMCID: PMC2892639.
• Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG.  Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep, 23:1537-1543, 2010.  PMID: 20428807.  PMCID: in process (NIHMS395054).
• Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F.  Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.Blood, 115:1185-93, 2010.  PMCID: PMC2826230.
• Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.Cancer Immunol Immunother, 59:529-540, 2010.  PMID: 19820934.  PMCID: in process (NIHMS395055).
• Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy J, Brufsky A, Chivukula M, Khoury T, Hsu D, Lyerly H, Clay T, Ferrone S.  CSPG4 as a new target for antibody-based immunotherapy of triple negative breast cancer.  J Natl Cancer Inst, 102:1496-1512, 2010.  PMCID: PMC2950168.
• zu Horste GM, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, Wiendl H, Kieseier BC.  Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies.Glia, 58:80-92, 2010.  PMID: 19544394.  PMCID: PMC3480724.
• Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M.  Interferon-? secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells.  Leuk Res, 35:275-277, 2011.  PMCID: PMC3021772.
• Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K.  Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck.Head Neck, 33:208-215, 2011.  PMID: 20848440.  PMCID: in process (NIHMS395061).
• Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, FerroneS, Kieber-Emmons T, Monzavi-Karbassi B.  Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selection ligands in aggressive breast cancer cells.  Breast Cancer Res, 13:R58, 2011.  PMID: 21658254.  PMCID: PMC3218947.
• Latzka J, Gaier S, Hofstetter G, Balazs N, Smole U, Ferrone S, Scheiner O, Breiteneder H, Pehamberger H, Wagner S.  Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One, 6:e19383, 2011.  PMID: 21573118.  PMCID: PMC3089623.
• Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL.  Natural killer (NK):  dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.  Immunol Res, 50:248-254, 2011.  PMID: 21717064.  PMCID: in process (NIHMS395027).
• Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.  Cancer Immunol Immunother, 6:525-535, 2011.  PMCID: PMC3426276.
• Mayayo SL, Prestigio S, Maniscalco L, Rosa GL, Aricò A, Maria RD, Cavallo F, Ferrone S, Buracco P, Iussich S.  Chondroitin sulfate proteoglycan-4:  a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J, 190:e26-e30, 2011.  PMID:  21482159.  PMCID: Not available.
• Morandi F, Corrias MV, Levreri I, Scaruffi P, Raffaghello L, Carlini B, Bocca P, Prigione I, Stigliani S, Amoroso L, Ferrone S, Pistoia V.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.  Cancer Immunol Immunother, 60:1485-1495, 20011.  PMCID: PMC3186874.
• Price MA, Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.  Pigment Cell Melanoma Res, 24:1148-1157, 2011.  PMID: 22004131.  PMCID: in process (NIHMS394813).
• Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B.  Association of IFN-{gamma} signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.  Clin Cancer Res, 17:2668-2678, 2011.  PMID: 21248298.  PMCID: in process (NIHMS394800).
• Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopouloum E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC.  Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.  Int J Cancer, 128:2663-2672, 2011.  PMID: 20715106.  PMCID: in process (NIHMS394811).
• Visus C, Wang YY, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside S, Ferrone S, Deleo A, and Wang X.  Targeting ALDHbright human carcinoma initiating cells with ALDH1A1-specific CD8+ T cells.  Clin Cancer Res, 17:6174-6184, 2011.
• Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S.  Functional characterization of an scFV antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.  Cancer Res, 71:7410-7422, 2011.  PMID: 22021902.  PMCID: in process (NIHMS394798).
• Zarour H, Ferrone S.  Cancer immunotherapy:  progress and challenges in the clinical setting.  Eur J Immunol, 41:1510-1515, 2011.  PMID: 21618503.  PMCID: in process (NIHMS394802).
• Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV.  Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.  Cancer Immunol Immunother, 2012.  PMID: 22258792.  PMCID: not available.
• Campoli M, Fitzpatrick JE, High W, Ferrone S.  HLA antigen expression in melanocytic lesions:  is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes?  J Am Acad Dermatol, 66:911-916, 2012.  PMCID: NIHMS28439.
• Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Beffa CD, Ferrone S, Bollo E.  MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.  Transl Oncol, 5:48-55, 2012.  PMCID: PMC3281407.
• Khoury T, Foluso A, Chandraseekhar R, DeLeo A, Ferrone S, Wang Y, Wang X. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.  Modern Pathol, 25:388-397, 2012.  PMID: 22080062.  PMCID: in process (NIHMS395026).
• Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.  Cancer Immunol Immunother, 61:789-801, 2012.  PMCID: PMC3365630.
• Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M.  CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.  Clin Cancer Res, 18:5352-5363, 2012.  PMID: 22893632.  PMCID: not available.
• Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R.  Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.  Br J Cancer, 106:939-946, 2012.  PMCID: PMC3305957.
• Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S.  Down-regulation of human leukocyte antigen class I heavy chain in tumors is associated with poor prognosis in advanced esophageal cancer patients.  Int J Oncol, 40:965-974, 2012.  PMID: 22134332.  PMCID: not available.
• Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.  Role of Apollon in human melanoma resistance to anti-tumor agents that activate the intrinsic or the extrinsic apoptosis pathways.  Clin Cancer Res, 18:3316-3327, 2012; PMID: 22553342.  PMCID: in process (NIHMS395277).
• Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL.EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.Oncoimmunology. 2:e27215. 2013. PMID: 24501692.
• Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol. 190:5856-5865, 2013. PMID: 23626012.
• Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer, 119:2737-46. 2013 PMID: 23695963.
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 133:624-636, 2013. PMID: 23364915. PMCID: 3663913.
• Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 19:798-808, 2013 PMID: 23363816. PMCID: 3578140. 
• Morandi B, Bonaccorsi I, Mesiti M, Conte R, Carrega P, Costa G, Iemmo R, Martini S, Ferrone S, Cantoni C, Mingari MC, Moretta L, Ferlazzo G.  Characterization of human afferent lymph dendritic cells from seroma fluids.  J Immunol. 191:4858-66, 2013. PMID: 24078697.
• Sabbatino F, Ferrone S. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clin Cancer Res.19:958-960, 2013. PMID: 23340298.
• Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PloS one. 8:e47234, 2013. PMID: 23408925. PMCID: 3567103.
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, Lopez-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 19:1858-1872, 2013. PMID: 23444227. PMCID: 3640274.
• Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 19:1816-26, 2013. PMID: 23401227. PMCID: 3618546.
• Wastowski IJ, Simoes RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Jr., Flajollet S, Jensen SS, Ferrone S, Carosella ED, Kristensen BW, Moreau P. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-gamma treatments: results from a multicentric study. Am J Pathol. 182:540-552, 2013.  PMID: 23219427. PMCID: 3562737.
• Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M6, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E.Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.Nat Commun. 5:5639,2014. PMID: 25472612.
• Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.J Immunother Cancer. 2:25, 2014.PMID: 25197555.
• Fauci JM, Sabbatino F, Wang Y, Londono-Joshi AI, Straughn JM, Jr. Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol.132:203-10, 2014. PMID: 24216048.
• Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.Oncotarget. 5:403-16, 2014. PMID: 24480782.
• Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann MM, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 20:962-71, 2014. PMID: 24334762.
• Leone P, Di Tacchio M, Berardi S, Santantonio T, Fasano M, Ferrone S, Vacca A, Dammacco F, Racanelli V.Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery.J Hepatol. pii: S0168-8278(14)00256-6, 2014. PMID: 24732300.
• Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I.IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation.J Immunol. 192:2634-42, 2014. PMID: 24554774.
• Riccardo F, Iussich S, Maniscalco L, Mayayo SL, Rosa GL, Arigoni M, Maria RD, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res. 20:3753-62, 2014. PMID: 24874834.
• Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR.PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Oncotarget. 2014. PMID: 24732172.
• Sabbatino F, Fusciello C, Somma D, Pacelli R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria Scarpati G, Ferrone S, Pepe S.Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.Cytometry A. 85:953-61, 2014.PMID: 25182801.
• Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L.HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.Neoplasia. 16:31-42, 2014. PMID: 24563618.
• Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Lezzi G, Terracciano L, Ferrone S.NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology.3:e952197,2014. PMID: 25610741.
• Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z.Programmed cell death ligand 1 expression in osteosarcoma.Cancer Immunol Res. 2:690-8, 2014.PMID: 24866169.
• Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maßen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A. Genetic evolution of T-cell resistance in the course of melanoma progression.Clin Cancer Res. 20:6593-604, 2014.PMID: 25294904.
• Volonte A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C. Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. J Immunol. 192:523-32,2014. PMID: 24277698.
• Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li J, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X. Blocking the formation of radiation–induced breast cancer stem cells Oncotarget. 5:3743-55, 2014.PMID: 25003837.
• Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 290:26562-75, 2015. PMID: 26381407.
• Fenton M, Whiteside TL, Ferrone S, Boyiadzis M.Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.Oncol Res. 22:117-21, 2015. PMID: 25706398.
• Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4+ Regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 75:2200-10, 2015. PMID: 25832655.
• Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E, Topp Z, Samlowski WE, McClay E, Bethel K, Ferrone S, Hicks J, Kuhn P.Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.Phys Biol.12:016008, 2015.PMID: 25574741.
• Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF, Ferrone S, Ferris RL. STAT1-Induced HLA Class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC Patients. Cancer Immunol Res. 3:936-45. 2015 PMID: 25972070.
• Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M, Kloor M.Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer.Cancer Immunol Immunother. 64:357-66, 2015. PMID: 25445815.
• Wang Y, Wang X, Ferrone CR, Schwab JH, Ferrone S. Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Mol Oncol. 9:1982-93, 2015. PMID: 26597109.
• Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G. Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. Oncotarget. 7:2070-9, 2016. PMID: 26655503.
• Conteduca G, Fenoglio D, Parodi A, Battaglia F, Kalli F, Negrini S, Tardito S, Ferrera F, Salis A, Millo E, Pasquale G, Barra G, Damonte G, Indiveri F, Ferrone S, Filaci G. AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget.7:60872-60884, 2016. PMID:27563821.
• Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 7:7390-402, 2016. PMID: 26862729.
• Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 22:470-8, 2016. PMID: 26373575.
• Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. Antitumor activity of BRAF inhibitor and IFNa combination in BRAF-mutant melanoma. J Natl Cancer Inst. 108, pii: djv435. doi: 10.1093 2016. PMID: 26851802.
• Schoenfeld AJ, Wang X, Wang Y, Hornicek FJ, Nielsen GP, Duan Z, Ferrone S, Schwab JH. CSPG4 as a prognostic biomarker in chordoma. Spine J 16:722-7, 2016. PMID: 26689475.
• Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol. 46:409-19, 2016. PMID: 26564811.
• Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Res.  22:5229-5237, 2016. PMID: 27217441.
• Villani V, Mahadevan KK, Ligorio M, Fernandez-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR. Phosphorylated histone H3 (PHH3) isa superior proliferation marker for prognosis of pancreatic neuroendocrine tumors. Ann Surg Oncol. 23(suppl 5):609-617, 2016. PMID: 27020585.
• .Al-Sukaini A, Hornicek FJ, Peacock ZS, Saban LB, Ferrone S, Schwab JH. Immune surveillance plays a role in locally aggressive giant cell lesions of bone. Clin Orthop Relat Res, 2017. PMID: 28725958.
• Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget 8:37646-37656, 2017. PMID: 28430580.
• Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X.  A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 409:9-19, 2017. PMID: 28864067.
• Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sannamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Karch SM, Schalper KA, Herbst RS, Politi K. Impaired HLA Class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 1420-1435, 2017. PMID:29025772.
• Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 47:23-30. 2017 PMID: 28104527.
• Piras LA, Riccardo F, Issuch S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol. In press 2017 PMID: 27146852.
• Ravindranath MH, Jucaud V, Ferrone S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: evaluation of beadsets from different manufacturers. J Immunol Methods 450:73-80, 2017. PMID: 28782523.
• Ravindranath MH, Jucaud V, Ferrone S. Corrigendum to Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers Journal of Immunological Methods, Volume 450, Year (2017), start page 73, end page 80.J Immunol Methods 460:125, 2018. PMID: 30055839.
• Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep 7:2290, 2017. PMID: 28536458.
• Romoli MR, Di Gennaro P, Gerlini G, Sestini S, Brandani P, Ferrone S, Borgognoni L. High antigen processing machinery component expression in Langerhans cells from melanoma patients’ sentinel lymph nodes. Cell Immunol. 320:29-37, 2017. PMID: 28870403.
• Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer. Clin Cancer Res. 23:707-716, 2017. PMID: 27496866.
• Wang X, Wang X, Gu J, Zhou M, He Z, Wang X, Ferrone S.Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP.Oncotarget. 8(69):113837-113846. PMID: 29371950.
• Wang X, Wang Y, Gu J, Zhou D, He Z, Wang X, Ferrone S. ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Sci Rep 7(1):9687, 2017. PMID: 28852196.
• Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, Clardy S, Huang CH, Pille C, Ferrone S, Yang R, Castro CM, Lee H, Del Castillo CF, Weissleder R.Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci Transl Med. 9:391, 2017. PMID: 28539469.
• Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S. Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother. 67(6): 999-1009, 2018. PMID:29487978.
• Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F.Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.Nat Commun.9(1):5097, 2018. PMID: 30504837.
• Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgst A, Ferrone S, Selbo PK. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochem Photobiol Sci. 17(5):539-551, 2018. PMID: 29565434.
• Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.Nucl Med Biol. 58:67-73, 2018. PMID: 29413459.
• Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. Corrigendum to ‘212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models’[Nucl Med Biol 58 (2018) 67-73].Nucl Med Biol. 61:71, 2018. PMID: 29705525.
• Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 19(4), 2018. PMID: 29561763.
• Ludwig S, Sharma P, Theodoraki MN, Pietrowska M, Yerneni SS, Lang S, Ferrone S, Whiteside TL.Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(-) Head and Neck Cancer Cell Lines.Front Oncol.8:445, 2018. PMID: 30370252.
• Maccalli C, Rasul KI, Elawad M, Ferrone S.The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018, 53:189-200. Review.PMID: 30261276.
• Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.Oral Oncol. 77:92-97, 2018. PMID: 29362132.
• Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.Constitutive and TNFa-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 10(430), 2018. PMID: 29491184.
• Pilla L, Ferrone S, Maccalli C. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther. 17:1-20, 2018. PMID: 29874943.
• Ravindranath MH, Filippone EJ, Mahowald G, Callender C, Babu A, Saidman S, Ferrone S.Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform.Immunol Res. 66(5):584-604, 2018. PMID: 30324227.
• Ravindranath MH, Jucaud V, Ferrone S. Corrigendum to Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers Journal of Immunological Methods, Volume 450, Year (2017), start page 73, end page 80.J Immunol Methods460:125, 2018. PMID: 30055839.
• Sabbatino F, Marra A, Liguori L, Scognamiglio G, Fusciello C, Botti G, Ferrone S, Pepe S.Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.J Immunother Cancer.6(1):12, 2018. PMID: 30458852.
• Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL.Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. J Extracell Vesicles. 7:1435138, 2018. PMID:29511460.
• Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, Taylor MS, Fernandez-Del Castillo C, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR.Role of Tumor Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).Clin Cancer Res. 2019 Jan 22. pii: clincanres.1401.2018. doi: 10.1158/1078-0432.CCR-18-1401. [Epub ahead of print].PMID: 30670493.
• Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 35(2):221; 2019.e8. doi: 10.1016/j.ccell.2019.01.002.PMID: 30753824.
• Fan S, Tian T, Chen W, Lv X, Lei X, Zhang H, Sun S, Cai L, Pan G, He L, Ou Z, Lin X, Wang X, Perez MF, Tu Z, Ferrone S, Tannous BA, Li J.Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating mitochondrial transcription.  Cancer Res. 2019 Jan 18. pii: canres.2505.2018. doi: 10.1158/0008-5472.CAN-18-2505. [Epub ahead of print].PMID: 30659020.
• Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY.High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.Oncologist. 2019 Feb 12. pii: theoncologist.2018-0794. doi: 10.1634/theoncologist.2018-0794. [Epub ahead of print]. PMID: 30755500.
• Tian T, Lv X, Pan G, Lu Y, Chen W, He W, Lei X, Zhang H, Liu M, Sun S, Ou Z, Lin X, Cai L, He L, Tu Z, Wang X, Tannous BA, Ferrone S, Li J, Fan S. Long noncoding RNA MPRL promotes mitochondrial fission and cisplatin chemosensitivity via disruption of pre-miRNA processing.Clin Cancer Res. 2019 Mar 18. pii: clincanres.2739.2018. doi: 10.1158/1078-0432.CCR-18-2739. PMID: 30885939.
• Sottile R, Federico G, Garofalo C, Tallerico R, Faniello MC, Quaresima B, Cristiani CM, Di Sanzo M, Cuda G, Ventura V, Wagner AK, Contrò G, Perrotti N, Gulletta E, Ferrone S, Kärre K, Costanzo FS, Carlomagno F, Carbone E. Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. Front Immunol. 2019 Feb 26;10:224. doi: 10.3389/fimmu.2019.00224. eCollection 2019. PMID: 30873154.
• Zeng B, Liao J, Zhang H, Fu S, Chen W, Pan G, Li Q, Chen W, Ferrone S, Wu B, Sun S, Hu J, Ahn MH, Lin Z, Yu D, Ou Z, Wang X, Mo F, Huang N, Hamilton JA, Li J, Fan S.Novel ANO5 mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia.Head Neck 41(1):230. 2019 PMID: 30554457.